Physician profile
Abby L Kushnir
NPI 1326216615
$1,052.62
in general payments reported to CMS, 2019-2025
15 companies · $312 in 2025
The $312 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.04 · 2020: $15.21 · 2021: $31.63 · 2022: $18.68 · 2023: $378 · 2024: $233 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $210.10 | 2021-2025 | Azstarys |
| Sanofi Pasteur INC. | $133.61 | 2021-2025 | |
| Lilly USA, LLC | $122.95 | 2024 | Zepbound |
| Novo Nordisk INC | $120.22 | 2023 | Wegovy |
| Ironshore Pharmaceuticals INC. | $88.25 | 2019-2024 | Jornay Pm |
| Alk-Abello, INC | $70.37 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $61.36 | 2023-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Kaleo, INC. | $46.80 | 2019-2021 | |
| Neos Therapeutics, LP | $38.71 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $36.97 | 2023-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $32.57 | 2025 | Jornay Pm |
| Sobi, INC | $30.76 | 2023 | |
| Alexion Pharmaceuticals, INC. | $24.30 | 2024 | Strensiq |
| Tris Pharma INC | $17.87 | 2024 | Dyanavel Xr |
| Pfizer INC. | $17.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Kushnir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.